Literature DB >> 35658433

Target Profiling of an Iridium(III)-Based Immunogenic Cell Death Inducer Unveils the Engagement of Unfolded Protein Response Regulator BiP.

Xiaolin Xiong1, Ke-Bin Huang2, Yuan Wang1, Bei Cao3, Yunli Luo1, Huowen Chen1, Yan Yang1, Yan Long1, Moyi Liu1, Albert S C Chan1, Hong Liang2, Taotao Zou1.   

Abstract

Clinical chemotherapeutic drugs have occasionally been observed to induce antitumor immune responses beyond the direct cytotoxicity. Such effects are coined as immunogenic cell death (ICD), representing a "second hit" from the host immune system to tumor cells. Although chemo-immunotherapy is highly promising, ICD inducers remain sparse with vague drug-target mechanisms. Here, we report an endoplasmic reticulum stress-inducing cyclometalated Ir(III)-bisNHC complex (1a) as a new ICD inducer, and based on this compound, a clickable photoaffinity probe was designed for target identification, which unveiled the engagement of the master regulator protein BiP (binding immunoglobulin protein)/GRP78 of the unfolded protein response pathway. This has been confirmed by a series of cellular and biochemical studies including fluorescence microscopy, cellular thermal shift assay, enzymatic assays, and so forth, showing the capability of 1a for BiP destabilization. Notably, besides 1a, the previously reported ICD inducers including KP1339, mitoxantrone, and oxaliplatin were also found to engage BiP interaction, suggesting the important role of BiP in eliciting anticancer immunity. We believe that the ICD-related target information in this work will help to understand the mode of action of ICD that is beneficial to designing new ICD agents with high specificity and improved efficacy.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35658433     DOI: 10.1021/jacs.2c02435

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   16.383


  1 in total

1.  The endoplasmic reticulum chaperone BiP: a target for immunogenic cell death inducers?

Authors:  Oliver Kepp; Lucillia Bezu; Guido Kroemer
Journal:  Oncoimmunology       Date:  2022-06-21       Impact factor: 7.723

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.